Jimmy LEE

• Informed customers of promotions to increase sales productivity and volume.

Responsible hospital - KMUH System, E-Da System, VGHKS, NCKU, Pingtung District Hospital

Responsible product-Humira-All indication /Rinvoq-IBD /Skyrizi-IBD,

§Pro Brand- Adalimumab Biosimilar

§ Establish an IBD interdisciplinary comorbidity seminar

§Establish a cross-hospital IBD treatment experience symposium

§Arrange KMUH/E-Da/NCKU-IBD MDT meeting

§Establish KMUH Young Talent IBD meeting

• Spearheaded initiatives to streamline internal communication channels within the sales team, improving overall productivity.

I often used the role of Humira in multiple indications to co-organize cross-disciplinary and cross-hospital activities with colleagues from other products. I used the activities to allow colleagues to quickly become familiar with customers and improve the operation of AbbVie drugs in various hospitals. Networks are more stronger

• Worked with sales team to collaboratively reach targets, consistently meeting or exceeding personal quotas.

From February 2022 to present, working for AbbVie Pharmaceuticals - I am very happy to be responsible for the king of Biologics - Humira. Of course, I am also facing the pressure of the patent expiration of the company's largest product. My colleagues who are responsible for other immune products are still familiar with this treatment field. But as long as there are any regional problems, I will do my best to help, letting my colleagues know that we are a team and can help each other. I serve as the main contact window of the hospital pharmacy to control the market fluctuations of my own products and competing products. Only by understanding the market can we operate the market effectively.

Responsible hospital - VGSKS/KMUH/E-Da Hospital/Pingtung District and MMHTT

Responsible product -Cosentyx -Rheumatology team

§2020 Q4 KMUH Pro Brand-Cosentyx (IL17 Grouping)

§2020 Actively communicate with doctors New case management program

§2021 Q1 Ach. 105%, Q2 Ach. 109%

§2021 1H Ach. 107%

Major Achievement

✧ Assist the company to re-establish the Central District

business team in 2019

✧ Personnel development in 2020 - Assist colleagues to be

promoted/obtain TBM,Mini White Tiger and Account leader

✧ In 2020 CSMUH successfully Pro brand-cosentyx

✧ In 2020, CMUH successfully Pro brand-cosentyx

~ Leadership experience ~

✓ Served as the 2020 CSMUH Account team Sponsor Manager

✓ Central District Speaker up platform

Responsible hospital-VGHKS/KMUH/Juan General Hospital

Responsible product-Cosentyx -Dermatology and Rheumatology team

~Major Achievement~

✧ 2019 1H achievement rate 101%

✧ In 2019, Cosentyx was successfully entered into the drug-

Juan General Hospital.

✧ 2018 achievement rate 111%

✧ In 2018, VGHKS blocked a competing product (Taltz) and

the Pharmaceutical Committee did not approve it.

✧ In 2018, Cosentyx was successfully Listing-VGHKS

✧ 2017 achievement rate 100.02%

✧ In 2017, Cosentyx successfully Listing cosentyx- Datong Hospital of KMUH System and DC’s main competitor Stelara.

~ Leadership experience ~

✓ 2018 Account team Review-Best Practice Case

✓ Served as the Account Team Leader ofVGHKS in 2018

✓ Assist regional directors to establish Cosentyx service team (business staff and PSP )

✓ Served as the 2017 IHD Central and South District Product Leader

Senior Specialist, at Janssen Pain team /Immune team 2010.7~ 2017.7 Responsible for hospitals - CGMHKS, VGHKS, KMUH, E-Da, NCKU, CMH, Tainan City. Responsible for products - Ultracet/Simponi/Stelara

~Major Achievement~

✧ 2016 NCKUH Listing Simponi

✧ 2016 CMH Listing Stelara

✧ 2015 E-da Listing Stelara

✧ 2014 E-da Listing Simponi

✧ 2014 KMUH Listing Simponi.

✧ 2013 KMUH Listing Stelara.

✧ Product line replacement in 2013-Simponi/Stelara

✧ In 2011, CGMHKS monthly consumption up to 200,000- 220,000 pills

✧ In November 2010, CGMHKS Ultracet usage exceeded 200,000 pills in a single month

Sales Representative, at Pfizer 2004.1~ 2010.6

Responsible hospital - Taitung District HP/ GP/ DS

Responsible Durg : Novarsc/Lipitor/Doxaben/Celebrex

~ Major Achievement ~

✧ 2007/2009, annual Top Sales.

✧Top Sales in 2007 (YTD 130%).

✧ 2006 CHTT Listing Doxaben XL, Lipitor 40mg

✧ 2005 MMHTT Listing Doxaben XL, Lipitor 40mg